Farmas USA

ONTY, en pre, +4,71%...

Un saludo

Framus eres un crack.

Bueno para estos tres dias unas buenas tilas nos van a hacer falta. Y yo el mkercoles con curro a tope, me veo pegado al móvil y a este hilo, no me cansaré de decirlo el mejor de pharmas en castellano.

Aprietan.... minimos 4,85
160k
AMRN

Venga, apuesto con una entradita a 4,5$, con ejecución en pre...
Si entrara y le diera por rebotar al alza, trailing stop super ajustado, y a pillar lo que fuera posible pillar...

Un saludo

AMRN

AMRN

Presionando en SA:

Amarin Corp. (AMRN) [...] in which guru fund managers collectively sold a net 1.09 mill. shares from their 3.18 mill. shares holdings from the prior quarter. This is in addition to the 7.14 mill. shares sold by guru fund managers in the prior 3 qtrs. AMRN shares are down ~55% in the last year.

seekingalpha.com/article/1743432-predicting-biotech-stock-moves-based-on-consensus-picks-by-legendary-fund-managers?source=intbrokers_regular

Leerink Swann mantiene calificación de outperform y dice que el lenguaje negativo del informe es lo que toca:

http://www.streetinsider.com/Analyst+Comments/Amarin+%28AMRN%29+Vascepa+Briefing+Documents+Raise+Questions+-+Leerink+Swann/8773088.html?si_client=intbro

Edito con otro más:

Since there is a well-established benefit in this patient population, which does not have an omega-3 prescription option, we believe that Vascepa is more likely to receive a positive vote than a negative vote based on risk/reward analysis. While Vascepa's cholesterol data isn't perfect, REDUCE-IT has now enrolled 6,000 patients and will provide the full data in 2016. Vascepa is also risk-free, and has been on the market for nine months.

Pros:

-Drug has been on the market for 9 months, proven efficacy and safety in the real world from MARINE

-Enormous unmet need in this patient population after statin therapy, even for just TG reduction

-Apparently reduces LDL-C, does not increase it like Lovaza

-The FDA is clearly not concerned about the risk profile of Vascepa. The only serious adverse event was a fatal myocardial infarction in the placebo arm. There were no notable increases in any unfavorable biomarkers in Vascepa patients.

-REDUCE-IT has 6,000 patients

-ANCHOR performed under SPA

Cons:

-ANCHOR was a 12-week study, and was not long enough to establish Vascepa as a treatment for cardiovascular risk

-Increases in lipid parameters in the ANCHOR placebo remain enigmatic

-The market had a clear negative reaction to the briefing documents, suggesting more confidence in a negative vote than before

http://seekingalpha.com/article/1743482-amarin-our-last-analysis-before-anchor-adcom-for-vascepa?source=intbrokers_regular

Articulo de ahora mismito
http://seekingalpha.com/article/1743482-amarin-our-last-analysis-before-anchor-adcom-for-vascepa?source=email_rt_article_readmore&app=1

AMRN

edito: sorry, articulo repetido.

Amrn El pre se desinfla....
Edito Vamos en positivo..
Edito Esto sube y sube...

- Estoy por apagar el PC hasta el miércoles. jejeje. Mucha suerte a todos !!
Alea iacta est !!!!